Jove
Visualize
Contact Us

Related Concept Videos

COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

1.2K
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
1.2K
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

3.3K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
3.3K
Chronic Obstructive Pulmonary Disease01:24

Chronic Obstructive Pulmonary Disease

3.2K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
3.2K
Chronic Obstructive Pulmonary Disease-I: Introduction01:20

Chronic Obstructive Pulmonary Disease-I: Introduction

4.0K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
4.0K
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features01:24

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

77
Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
77
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

2.1K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
2.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Case of <i>Raoultella Ornithinolytica</i> Cholangitis in A Liver Transplant Recipient.

European journal of case reports in internal medicine·2024
Same author

Can a training hub deliver undergraduate medical education with patient educators?

Education for primary care : an official publication of the Association of Course Organisers, National Association of GP Tutors, World Organisation of Family Doctors·2022
Same author

An evaluation of a student-led career profiling project to support the exploration of a career in general practice and other specialties.

BJGP open·2022
Same author

Undergraduate medical teaching with remote consultations in general practice: a realist evaluation.

BJGP open·2022
Same author

The longitudinal integrated clerkship: A student insight.

The clinical teacher·2021
Same author

GP registrars teaching medical students- an untapped resource?

Education for primary care : an official publication of the Association of Course Organisers, National Association of GP Tutors, World Organisation of Family Doctors·2020
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 7, 2026

Author Spotlight: Efficacy of Auricular Pressure Bean Therapy in Reducing Wheezing Symptoms
02:34

Author Spotlight: Efficacy of Auricular Pressure Bean Therapy in Reducing Wheezing Symptoms

Published on: May 10, 2024

2.3K

Beclometasone for chronic obstructive pulmonary disease.

Daan A De Coster1, Melvyn Jones, Nikita Thakrar

  • 1Department of Primary Care and Population Health, University College London, Upper 3rd Floor, UCL Medical School (Royal Free Campus), Rowland Hill Street, London, UK, NW3 2PF.

The Cochrane Database of Systematic Reviews
|October 10, 2013
PubMed
Summary

Beclometasone dipropionate (BDP) shows limited evidence of effectiveness or safety in chronic obstructive pulmonary disease (COPD) compared to placebo or long-acting beta2-agonists (LABAs). Statistically significant findings were often not clinically meaningful or based on single studies.

More Related Videos

Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease
07:10

Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease

Published on: August 24, 2019

9.4K
Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure
08:17

Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure

Published on: August 25, 2017

10.7K

Related Experiment Videos

Last Updated: May 7, 2026

Author Spotlight: Efficacy of Auricular Pressure Bean Therapy in Reducing Wheezing Symptoms
02:34

Author Spotlight: Efficacy of Auricular Pressure Bean Therapy in Reducing Wheezing Symptoms

Published on: May 10, 2024

2.3K
Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease
07:10

Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease

Published on: August 24, 2019

9.4K
Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure
08:17

Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure

Published on: August 25, 2017

10.7K

Area of Science:

  • Pulmonology
  • Pharmacology
  • Clinical Trials

Background:

  • Chronic obstructive pulmonary disease (COPD) diagnosis relies on specific lung function criteria (FEV1/FVC < 0.70).
  • Inhaled corticosteroids (ICS) are recommended for severe COPD (GOLD stages 3-4, groups C-D) in combination with long-acting beta2-agonists (LABAs).
  • The safety and efficacy of beclometasone dipropionate (BDP), an unlicensed ICS, remain controversial, particularly regarding adverse effects like pneumonia.

Purpose of the Study:

  • To evaluate the effectiveness and safety of inhaled beclometasone (BDP) monotherapy versus placebo in COPD patients.
  • To assess the effectiveness and safety of BDP in combination with LABAs compared to LABAs alone for COPD management.

Main Methods:

  • Systematic review and meta-analysis of randomized controlled trials (RCTs) in stable COPD.
  • Searched multiple databases (CAGR, MEDLINE, EMBASE, etc.) up to February 2013.
  • Included RCTs comparing BDP vs. placebo or BDP/LABA vs. LABA with a minimum duration of 12 weeks.

Main Results:

  • Limited data for BDP vs. placebo showed no significant improvements in lung function, mortality, exacerbations, or dyspnea; evidence quality was low to very low.
  • For BDP/LABA vs. LABA, one study showed a statistically significant but likely not clinically significant improvement in FEV1 and days without rescue bronchodilators.
  • BDP/LABA was associated with a statistically significant increase in hospitalizations for exacerbations, though this finding is debated; no significant differences were found for mortality or pneumonia.

Conclusions:

  • There is minimal evidence supporting beclometasone as a safer or more effective COPD treatment option.
  • Statistically significant findings were often not clinically meaningful or derived from single studies, limiting definitive conclusions.
  • Further research, including ongoing studies, is needed to fully elucidate the role of BDP in COPD management.